Dec 23, 2025
Credo Technology Group Unusual Options Activity For December 23

Financial giants have made a conspicuous bullish move on Credo Technology Group. Our analysis of options history for Credo Technology Group (NASDAQ:CRDO) revealed 20 unusual trades. Delving into the details, we found 50% of traders were bullish, while 30% showed…

Dec 23, 2025
IBM Unusual Options Activity For December 23

Deep-pocketed investors have adopted a bullish approach towards IBM (NYSE:IBM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a…

Dec 23, 2025
Check Out What Whales Are Doing With MRK

Whales with a lot of money to spend have taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 13 trades. If we consider the specifics of each trade, it…

Dec 23, 2025
A Look Into Alaska Air Gr Inc’s Price Over Earnings

In the current market session, Alaska Air Gr Inc. (NYSE:ALK) share price is at $52.76, after a 1.35% drop. Over the past month, the stock spiked by 25.13%, but over the past year, it actually decreased by 22.96%. With good…

Dec 23, 2025
Santa Claus Rally Favors These 5 Stocks, History Says

As traders enter the final trading week of the year, one familiar question dominates Wall Street chatter: Will the Santa Claus Rally show up again? • Newmont stock is trading near recent highs. What should traders watch with NEM? History says…

Dec 23, 2025
Stock Market Hours This Week: Christmas 2025 Holiday Schedule

Investors planning ahead for the 2025 holiday season should be aware of the upcoming stock market closures and shortened trading days.   The SPY is climbing into Christmas. See the chart here.  President Donald Trump recently issued an executive order closing…

Dec 23, 2025
Pfizer Reports Patient Death In Marstacimab Hemophilia Extension Study

Pfizer Inc. (NYSE:PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce…